Johan Hansson
Experienced in Neuroendocrine Tumor

Johan Hansson

Stockholm, AB, SE 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Neuroendocrine Tumor
Stockholm, AB, SE 
OverviewLocationsClinical Research

Overview

Johan Hansson practices in Stockholm, Sweden. Mr. Hansson is rated as an Experienced expert by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Melanoma, Basal Cell Skin Cancer, Nevoid Basal Cell Carcinoma Syndrome, Familial Pancreatic Cancer, and Cystectomy.

His clinical research consists of co-authoring 154 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 5 clinical trials in the study of Neuroendocrine Tumor.

Gender
Male

Locations

Stockholm, AB 17176, Sweden
Other Locations
Oestersund, Z, Sweden
Patient Area Head And Neck, Solna, AB, Sweden
Goeteborg, O 41345, Sweden
Uppsala, C, Sweden
Karolinska Institutet, Sweden

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Prospective Randomized Multicenter Trial to Assess the Role of Imaging During Follow Up After Radical Surgery of Stage IIb-c and III Cutaneous Malignant Melanoma
A Prospective Randomized Multicenter Trial to Assess the Role of Imaging During Follow Up After Radical Surgery of Stage IIb-c and III Cutaneous Malignant Melanoma
Enrollment Status: Recruiting
Publish Date: December 16, 2024
Intervention Type: Procedure
Study Phase: Not Applicable
A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation
A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation
Enrollment Status: Completed
Publish Date: June 07, 2024
Intervention Type: Drug
Study Drugs: LGX818, MEK162, Nivolumab, Ipilimumab
Study Phase: Phase 2
Multicenter Phase 2 Study to Identify of the Optimal Neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)
Multicenter Phase 2 Study to Identify of the Optimal Neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)
Enrollment Status: Active_not_recruiting
Publish Date: November 15, 2023
Intervention Type: Procedure, Drug
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drugs: Ipilimumab, IMO-2125
Study Phase: Phase 3
Exploratory Study on Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma
Exploratory Study on Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma
Enrollment Status: Terminated
Publish Date: July 07, 2021
Intervention Type: Device
Study Phase: Not Applicable
View 4 Less Clinical Trials

154 Total Publications

Inhaled ciclesonide in adults hospitalised with COVID-19: a randomised controlled open-label trial (HALT COVID-19).
Inhaled ciclesonide in adults hospitalised with COVID-19: a randomised controlled open-label trial (HALT COVID-19).
Journal: BMJ open
Published: February 22, 2023

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hansson's expertise for a condition
ConditionClose
View All 9 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile